Aravive Biologics, Inc.
Records under this name other than the patents Aravive Biologics, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Showing 1 to 5 of 5 · Back to Aravive Biologics, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,879,061 | Inhibition of AXL/GAS6 Signaling in the Treatment of Liver Fibrosis Lapsed on the fee record Ended Jan 30, 2026 · High confidence | Lapsed on the fee record | Ended Jan 30, 2026 | High confidence |
| US 9,822,347 | Modified AXL Peptides and Their Use in Inhibition of AXL Signaling in Anti-Metastatic Therapy Lapsed on the fee record Ended Nov 21, 2025 · High confidence | Lapsed on the fee record | Ended Nov 21, 2025 | High confidence |
| US 11,136,563 | Modified Axl Peptides and Their Use in Inhibition of Axl Signaling in Anti-Metastatic Therapy Lapsed on the fee record Ended Oct 5, 2025 · High confidence | Lapsed on the fee record | Ended Oct 5, 2025 | High confidence |
| US 9,296,732 | Substituted Benzamides and Their Uses Lapsed on the fee record Ended Mar 29, 2020 · High confidence | Lapsed on the fee record | Ended Mar 29, 2020 | High confidence |
| US 9,085,570 | Substituted Benzamides and Their Uses Lapsed on the fee record Ended Jul 21, 2019 · High confidence | Lapsed on the fee record | Ended Jul 21, 2019 | High confidence |